| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 12/11/2001 | US6329379 Oligopeptides for inhibiting hepatitis |
| 12/11/2001 | US6329365 Inhibitors of interleukin-1β converting enzyme |
| 12/11/2001 | US6329363 Cephalosporin antibiotics |
| 12/11/2001 | US6329345 13-membered azalides and their use as antibiotic agents |
| 12/11/2001 | US6329339 Lactoferrin with glycyrrhizic acid as synergist |
| 12/11/2001 | US6329202 Antibodies directed against binding associated epitopes |
| 12/11/2001 | US6328997 Magnesium bicarbonate |
| 12/11/2001 | US6328989 Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli |
| 12/11/2001 | US6328984 Selective antibacterial composition |
| 12/11/2001 | US6328978 Methods for the treatment of immunologically-mediated skin disorders |
| 12/11/2001 | US6328973 Method of raising neutralizing antibodies against HIV |
| 12/11/2001 | US6328972 Compositions and methods for inducing cytotoxic T lymphocyte responses by immunization with protein antigens |
| 12/11/2001 | US6328967 Delivery system to modulate immune response |
| 12/11/2001 | US6328962 Conjugate molecules are produced by genetic modification of genes encoding light and heavy chains of the surface structure specific antibody and expression in mammal cells to produce the conjugated antibody; enhanced immune response |
| 12/11/2001 | US6328955 Method for regulating IL-10 with IL-9, and applications thereof |
| 12/11/2001 | US6328954 Use of the IL-4 receptor for the therapy prophylaxis and diagnosis of allergic viral parasitic and bacterial diseases and of fungal infections |
| 12/11/2001 | CA2329482C Recombinant antibodies specific for tnf-.alpha. |
| 12/11/2001 | CA2213108C 2-aminobenzazapine derivatives |
| 12/11/2001 | CA2162132C Hepatitis b virus mutants, reagents and methods for detection |
| 12/11/2001 | CA2136429C Combined vaccines comprising hepatitis b surface antigen and other antigens |
| 12/11/2001 | CA2117953C Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same |
| 12/11/2001 | CA2066053C Recombinant retroviruses delivering vector constructs to target cells |
| 12/11/2001 | CA1341325C Triazole antifungal agents |
| 12/09/2001 | CA2349960A1 Ibdv strain for in ovo administration |
| 12/06/2001 | WO2001092584A1 Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
| 12/06/2001 | WO2001092562A2 Inhibiting retroviral integration by targeting the atm pathway |
| 12/06/2001 | WO2001092547A2 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | WO2001092534A1 Biological materials and methods for use in the prevention or treatment of infections |
| 12/06/2001 | WO2001092530A1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide |
| 12/06/2001 | WO2001092527A2 Regulators of apoptosis |
| 12/06/2001 | WO2001092513A1 METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi |
| 12/06/2001 | WO2001092490A2 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 12/06/2001 | WO2001092474A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | WO2001092340A2 Use of interleukin-4 antagonists and compositions thereof |
| 12/06/2001 | WO2001092333A2 Use of adnf for enhancing learning and memory |
| 12/06/2001 | WO2001092312A1 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 12/06/2001 | WO2001092311A2 Convergent combinatory peptide libraries and their use for vaccination against hepatitis c virus |
| 12/06/2001 | WO2001092304A2 Transporters and ion channels |
| 12/06/2001 | WO2001092288A2 Cobalamin compounds useful as antibiotic agents and as imaging agents |
| 12/06/2001 | WO2001092282A2 Methods and compositions for treating flaviviruses and pestiviruses |
| 12/06/2001 | WO2001092281A1 Method used for transforming the carbonyl function in position 4'' of a cladinose unit of an aza macrolide into an amine derivative |
| 12/06/2001 | WO2001092280A1 Hygromycin a derivatives for the treatment of bacterial and protozoal infections |
| 12/06/2001 | WO2001092253A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 12/06/2001 | WO2001092232A1 4-aminoquinolines as antiinfective agents |
| 12/06/2001 | WO2001092230A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 12/06/2001 | WO2001092227A1 Chemical compounds |
| 12/06/2001 | WO2001092220A1 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof |
| 12/06/2001 | WO2001092218A2 Polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | WO2001092202A1 Il-8 receptor antagonists |
| 12/06/2001 | WO2001091803A2 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 12/06/2001 | WO2001091798A2 Tumor activated prodrug compounds |
| 12/06/2001 | WO2001091790A1 Vaccine composition |
| 12/06/2001 | WO2001091788A1 Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof |
| 12/06/2001 | WO2001091787A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | WO2001091786A2 Diagnosis and treatment of herpes infections |
| 12/06/2001 | WO2001091780A1 Neuroprotective peptides |
| 12/06/2001 | WO2001091775A2 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity |
| 12/06/2001 | WO2001091761A1 Matrices for oral preparations |
| 12/06/2001 | WO2001091758A1 Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof |
| 12/06/2001 | WO2001091737A2 Methods for treating hepatitis delta virus infection with beta-l-2' deoxy-nucleosides |
| 12/06/2001 | WO2001091711A1 Use of exogenous lactic bacteria strain against actinomyces naeslundii related diseases |
| 12/06/2001 | WO2001091682A1 Composition and applicator for topical substance delivery |
| 12/06/2001 | WO2001091536A2 Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens |
| 12/06/2001 | WO2001046392A3 Homologues of human heparanase and splice variants thereof |
| 12/06/2001 | WO2001045732A3 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 12/06/2001 | WO2001041702A3 Zinc thiosalicylate, dermatological compositions containing same, in particular in the form of a self-adhesive device and method for preparing same |
| 12/06/2001 | WO2001034646A3 Recombinant gelatins |
| 12/06/2001 | WO2001025257A3 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 12/06/2001 | WO2001023421B1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 12/06/2001 | WO2001023362A3 Rate-controlled particles |
| 12/06/2001 | WO2001018042A3 Apoptosis proteins |
| 12/06/2001 | WO2001014416A3 Synthetic papillomavirus genes optimized for expression in human cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001010847A8 Novel integrin receptor antagonists |
| 12/06/2001 | WO2000077206A3 The myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | WO2000077018A3 Purine derivatives |
| 12/06/2001 | WO2000064427A3 Lamivudine containing pharmaceutical formulation |
| 12/06/2001 | WO2000011036A9 AN ANTI-CYANOVIRIN ANTIBODY WITH AN INTERNAL IMAGE OF gp120, A METHOD OF USE THEREOF, AND A METHOD OF USING A CYANOVIRIN TO INDUCE AN IMMUNE RESPONSE TO gp120 |
| 12/06/2001 | WO2000006599A8 Inhibitors of hiv membrane fusion |
| 12/06/2001 | US20010049435 Myostatin gene promoter and inhibition of activation thereof |
| 12/06/2001 | US20010049383 Gram-positive oxazolidinone agent; contact surface material is made of at least 50% polyolefin. |
| 12/06/2001 | US20010049372 Antiviral nucleoside analogues |
| 12/06/2001 | US20010049371 Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases |
| 12/06/2001 | US20010049145 Hepatitis B virus vectors for gene therapy |
| 12/06/2001 | US20010049142 A rapid, simple-to-use method to differentiate nondividing cells by fusing two different cells and then purifying them without antibiotic or metabolic selection; kits with two nontoxic dyes and instructions; antitumor agents |
| 12/06/2001 | US20010049137 DNA fragments derived from the genomic DNA of HPV-33, including recombinant vectors, which cells are replicated in host cells and expressed as immunogenic proteins; diagnosis of tumors; antibodies to detect viral infections |
| 12/06/2001 | US20010049122 For reducing inflammation, for treating an autoimmune disease, for enhancing transplantation of tissue grafts, increasing antitumor immunity, and inhibiting viral and parasitic infections |
| 12/06/2001 | US20010049113 Treating a vial infection which uses the host cell Ras pathway with agents that inhibit Ras pathway, agents that promote protein kinase (PKR) phosphorylation, or that promote translation initiation factor eIF-2 alpha phosphorylation |
| 12/06/2001 | US20010048929 Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| 12/06/2001 | US20010048928 Herpesvirus particles comprising fusion protein and their preparation and use |
| 12/06/2001 | CA2414017A1 Inhibiting retrotransposon and retroviral integration by targeting the atm pathway |
| 12/06/2001 | CA2411323A1 Il-8 receptor antagonists |
| 12/06/2001 | CA2410947A1 Methods for mediating gene suppresion by using factors that enhance rnai |
| 12/06/2001 | CA2410935A1 Novel polyamine analogues as therapeutic and diagnostic agents |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410886A1 Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof |
| 12/06/2001 | CA2410736A1 Alpha (2) macroglobulin receptors as a heat shock protein receptor and uses thereof |
| 12/06/2001 | CA2410735A1 Use of adnf for enhancing learning and memory |
| 12/06/2001 | CA2410665A1 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | CA2410652A1 Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof |